Top Markets
#1 Zora Zora +31.06%
#2 Tutorial Tutorial +29.43%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +25.39%
#4 GALA GALA +25.38%
#5 Fabric Protocol Fabric Protocol +24.31%
#6 Pieverse Pieverse +23.14%
#7 HashKey Platform Token HashKey Platform Token +22.61%
#8 Arowana Arowana +22.11%
#9 Derive Derive +21.73%
#10 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +20.51%
Coin of the day
Zora Zora
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Sirnaomics Ltd. Sirnaomics Ltd.

Sirnaomics Ltd.

2257
Kedudukan dalam Saham #25049
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in... Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
Harga Saham
$0.49443488
Modal Pasaran
$53.84M
Perubahan (1 hari)
-0.90%
Perubahan (1 tahun)
-60.89%
Negara
US
Perdagangan Sirnaomics Ltd. (2257)

Kategori

Healthcare
Pendapatan untuk Sirnaomics Ltd. (2257)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Sirnaomics Ltd., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Sirnaomics Ltd. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH